CHOICE2 randomized 400 patients across 14 Spanish centers to thrombectomy alone versus thrombectomy plus intraarterial alteplase, with 90-day mRS as the primary endpoint. Excellent outcomes (mRS 0–1) ...

Alteplase is the standard agent used in early reperfusion therapy, but alternative thrombolytic agents are needed. The efficacy and safety of reteplase as compared with alteplase in patients with ...

When treating patients with acute ischemic stroke within 4.5 hours of symptom onset, tenecteplase provides noninferior outcomes compared with alteplase (Activase; Genentech), with similar safety, ...

Please provide your email address to receive an email when new articles are posted on . In a phase 2 study, reteplase demonstrated similar efficacy and safety vs. alteplase for the treatment of acute ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

A new trial has found the thrombolytic reteplase to be superior to alteplase in patients with acute ischemic stroke presenting within 4.5 hours of symptom onset, with an excellent functional outcome ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Giving the clot-busting medication alteplase at the site of a blocked brain artery after blood clot removal may increase the number of patients who fully recover, according to preliminary ...

Researchers found that the percentage of patients with functional independence at 90 days was higher in the alteplase group vs the standard treatment group. HealthDay News — For patients with mainly ...